NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors, media and the general public to view and listen to a webcast of a conference call with investment analysts at 1:00 p.m. EDT on Friday, June 12, 2009. The purpose of the call is to review Phase 2 data for CP-690,550, Pfizer’s oral JAK-3 inhibitor, that will be presented during the Annual Congress of the European League Against Rheumatism (EULAR).
